EMA accepts Henlius’ MAA for trastuzumab biosimilar HLX02

Henlius announces that EMA has accepted Henlius’ MAA for trastuzumab biosimilar HLX02. This is the first Chinese developed TmAb biosimilar to be accepted for review by the EMA.